NCT04322890

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6,000 (estimated)
• Sponsor: Hunan Province Tumor Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Detailed description

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation. Our study was set up with several group with EGFR mutant, ALK fusion, ROS1 fusion, RET fusion, BRAF mutation, NRG1 fusion, MET alteration, KRAS mutation, etc.

Conditions

• Non Small Cell Lung Cancer
• EGFR Gene Mutation
• ALK Gene Mutation
• ROS1 Gene Mutation
• MET Gene Mutation

Interventions

Type	Name	Description
DRUG	Osimertinib	Osimertinib 80mg, po, qd;
DRUG	Alectinib 150 MG	Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
DRUG	Crizotinib 250 MG	Crizotinib 250 MG po bid.
DRUG	Savolitinib, Crizotinib.	Savolitinib, 300mg po qd.
DRUG	Chemotherapy	500mg, ivgtt, every 21day.

Timeline

• Start date: 2020-04-16
• Primary completion: 2026-12-24
• Completion: 2027-12-24
• First posted: 2020-03-26
• Last updated: 2024-10-22

Locations

1 site across 1 country: China